作者:Julie A. Spicer、Christian K. Miller、Patrick D. O'Connor、Jiney Jose、Kristiina M. Huttunen、Jagdish K. Jaiswal、William A. Denny、Hedieh Akhlaghi、Kylie A. Browne、Joseph A. Trapani
DOI:10.1016/j.bmcl.2016.12.057
日期:2017.2
The pore-forming protein perforin is a key component of mammalian cell-mediated immunity and essential to the pathway that allows elimination of virus-infected and transformed cells. Perforin activity has also been implicated in certain auto-immune conditions and therapy-induced conditions such as allograft rejection and graft versus host disease. An inhibitor of perforin activity could be used as a highly specific immunosuppressive treatment for these conditions, with reduced side-effects compared to currently accepted therapies. Previously identified first-in-class inhibitors based on a 2-thioxoimidazolidin-4-one core show suboptimal physicochemical properties and toxicity toward the natural killer (NK) cells that secrete perforin in vivo. The current benzenesulphonamide-based series delivers a non-toxic bioisosteric replacement possessing improved solubility. (C) 2017 The Authors. Published by Elsevier Ltd.